glp-1 obesity drugs updates today Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Are Difficult to Afford GLP-1 anti-obesity drugs lead to

In June 2025, Eli Lilly reported Phase III ACHIEVE-1 Survodutide (BI 456906): Boehringer Ingelhium Survodutide (BI 456906) is a GCGR/GLP1 dual agonist being developed by Boehringer Ingelhium

The pancreatic-endocrine-osseous axis involves a potential link between DPP-4, bone, and energy metabolism through the receptor activator of nuclear factor kappa B ligand (RANKL), which induces DPP-4 expression in osteoclasts, leading to decreased GLP-1 levels and increased blood glucose levels

however, the increased risk and severity of this complication prompted the EMA to warn patients

doi: 10.1016/j.molmet.2022.101638 87 GasbjergLSHelstedMMHartmannBSparre-UlrichAHVeedfaldSStensenSet al

Insurance Coverage Trulicity: Often on diabetes medication formularies May be preferred due to established relationships with Eli Lilly Prior authorization typically required Ozempic: Also commonly covered for diabetes May face step therapy requirements Prior authorization typically required Coverage varies by plan: Some plans prefer one medication over the other based on rebate agreements

Pure Impact delivers high-intensity electromagnetic stimulation to deep and fast-twitch muscle fibres, provoking supramaximal contractions beyond what is typically possible through voluntary exercise alone